Spet investigations in extrapyramidal diseases using specific ligands

Nuclear Medicine Communications

Volumn 18, Issue 2, 1997, Pages 159-163

  Staffen, W ^a   Hondl, N ^a   Trinka, E ^a   Zenzmaier, R ^a   Ladurner, G ^a  

^a Landesuervenklinik Salzburg ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BETA CIT I 123; IBZM I 123; IODINE 123; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUNTINGTON CHOREA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILSON DISEASE;

EID: 0030946737     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199702000-00011     Document Type: Article

References (44)

1. Allard P, Alafuzoff J, Carlsson A et al Loss of dopamine uptake sites labelled with [3H]-GBR-12935 in Alzheimer’s disease. Eur Neurol 1990: 30: 181-185.
2. Arnoki G, Tatsch K, Oertel WH et al Clinical progressive supranuclear palsy: Differential diagnosis by IBZM-SPECT and MRI. J Neural Transm 1994; 42 (suppl.): 111-118.
3. Boja JW, Patel A, Carroll FI et al [125I]-RTI-55: A patent ligand for dopamine transporters. Eur J Pharmacol 1991; 194: 133-134.
4. Booij J, Vermeulen J, Tissingh G et al Visualization of the dopamine transporter in Parkinson’s disease and multiple system atrophy: A [123I] p-CIT study (abstract). Acta Neurolog Belg 1995; 95 (suppl.): 35.
5. Brücke T, Wenger S, Asenbaum S et al Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11: 220-228.
6. Brücke T, Kornhuber J, Angelberger P et al SPECT imaging of dopamine and serotonin transporters with [123I] p-CIT: Binding kinetics in the human brain. J Neural Transm 1993; 94: 137-146.
7. Brücke T, Tsai YF, McLellan C et al In vitro binding properties and autoradiographic imaging in 3-iodobenzamide [125I] IBZM: A potential imaging ligand for D2 dopamine receptors in SPECT. Life Sci 1988; 42: 2097-2104.
8. Cross A, Rossor M. Dopamine D1 and D2 receptor in Huntington’s disease. Eur J Pharmacol 1983; 88: 223-229.
9. Farde L, Hall H, Ehrin E et al Quantitative analysis of dopamine D2 receptor binding in the living human brain by PET. Science 1986; 231: 258-261.
10. Garnett ES, Finnan G, Nahmias G. Dopamine visualized in the basal ganglion of living man. Nature 1983; 305: 137-138.
11. Giobbe D, Castellano GC, Podio V. Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson’s disease. Hal J Neurol Sci 1993; 14: 165-169.
12. Harasko van der Meer C, Brücke T, Wenger S et al Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm 1993; 94: 217-221.
13. Hatazawa J. The effect of neuroleptics on human brain estimated by SPECT and PET. Kaku Igaku 1993; 30: 687-692.
14. Hierholzer J, Cordes M, Schelosky L et al Dopamine D2 receptor imaging with iodine123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med 1994; 35: 1921-1927.
15. Hierholzer J, Cordes M, Schelosky L et al The determination of cerebral dopamine D2 receptor density by using [123I]-IBZM-SPECT in Parkinson disease patients. Rofo Fortschr Geb Röntgenstr neuen Bildgeb Verfahr 1992; 157: 390-398.
16. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
17. Ichise M, Toyama H, Fornazzari L et al. Iodine-123 IBZM dopamine D2 receptor and technetium-99m HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington’s disease. J Nucl Med 1993; 34: 1274-1281.
18. Innis RB, Seibyl JP, Wallace E et al. SPECT imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. J Nucl Med 1993; 34: 31.
19. Kung HF, Kasliwal R, Pan S et al. Dopamine D2 receptor imaging radiopharmaceuticals: Synthesis, radiolabelling, and in vitro binding of (R)-(+)-and (S)-(-)-3iodo-2hydroxy-6methoxy-N-[lethyl-2pyrrolidinyl-methyl] benzamide. J Med Chem 1988; 31: 1039-1043.
20. Kung HF, Alavi A, Chang W et al. In vitro SPECT imaging of dopamine receptors: Initial studies with iodine 123-IBZM in humans. J Nucl Med 1991; 31: 573-579.
21. Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H] paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 1988; 24: 299-309.
22. Laruelle M, Wallace E, Seibyl JP et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] p-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
23. Matsumura K, Toyama H, Nakashima H et al. In vivo characteristics of IBZM in rat brains: An agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties. Kagu Igaku 1994; 31: 513-519.
24. Menzel C, Griinwald F, Klemm E et al. Brain SPECT with,23I-labelled iodobenzamide (IBZM): Aspects of semiquan-titative evaluation. Nuklearmedizin 1993: 32: 227-230.
25. Morgan DG, Marcusson JO, Nyberg P et al. Divergent changes in D, and D2 dopamine binding sites in human brain during aging. Neurobiol Aging 1987; 8: 195-201.
26. Neumeyer JL, Wang S, Milius PA et al. [123I]-2-carboxy methoxy-31-(4iodophenyl) tropane p-CIT: High affinity SPECT radiotracer of monoamine re-uptake sites in brain. J Med Chem 1991; 34: 3144-3146.
27. Niznik HB, Fogel EF, Fasso FF et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56: 192-198.
28. Oetrel WH, Tatsch K, Schwarz J et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol 1992; 32: 743-748.
29. Perry EK, Marshall EF, Blessed G et al. Decreased imipra-mine binding in the brain of patients with depressive illness. Br J Psychiatry 1983; 142: 188-192.
30. Podreka I, Höll K, DalBianco P et al. Klinische und tech-nische Aspekte der SPECT-Hirnszintigraphie mit [123I]-N-Isopropyl-Amphetamin. Nuc Compact 1984; 15: 305-314.
31. Podreka I, Baumgartner C, Suess E et al. Quantification of regional cerebral blood flow with IMP-SPECT: Reproducibility and clinical relevance of flow values. Stroke 1989; 20: 183-191.
32. Saha GB, MacIntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. Sem Nucl Med 1994; 24: 324-349.
33. Seibyl JP, Woods SW, Zoghbi SS et al. Dynamic SPECT imaging of dopamine D2 receptor in human subjects with iodine123-IBZM. J Nucl Med 1992; 33: 1964-1971.
34. Shao L, Billings J, Pfeiffer N et al. Concentration recovery for SPECT CNS dopamine receptor studies for monkeys. Med Phys 1994; 21: 675-681.
35. Schelosky L, Hierholzer J, Wissel J et al. Correlation of clinical response in apomorphine test with D2 receptor status as demonstrated by,23I-IBZM SPECT. Mov Disord 1993; 8: 453-458.
36. Schulu JB, Klockgether T, Petersen D et al. Multiple system atrophy: Natural history, MRI morphology, and dopamine receptor imaging with 123I-IBZM SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056.
37. Schwarz J, Antonini A, Kraft E et al. Comparison of,23I-IBZM and C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994; 15: 806-813.
38. Schwarz J, Antonini A, Kraft E et al. Treatment with D-penicillamine improves dopamine D2 receptor binding and T2-signal intensity in de novo Wilson’s disease. Neurology 1994; 44: 1079-1082.
39. Schwarz J, Tatsch K, Arnold G et al. 123I-iodobenzamide SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43: 817-820.
40. Schwarz J, Tatsch K, Vogl T et al. Marked reduction of striatal dopamine D2 receptors as detected by 123I-IBZM-SPECT in a Wilson’s disease patient with generalized dystonia. Mov Disord 1992; 7: 58-61.
41. Toyama H, Matsumura K, Nakashima H et al. In vivo characteristics of IBZM in rat brains: An agent for quantitative SPECT imaging of D2 dopamine receptor density using equilibrium analysis. Kagu Igaku 1994; 31: 1117-1120.
42. Toyama H, Ichise M, Ballinger JR et al. Dopamine D2 receptor SPECT imaging: Basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med 1993; 7: 29-38.
43. Wober C, Brücke T, Wober-Bingol C et al. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Celphalgia 1994; 14: 135-140.
44. Wong DF, Wagner HN, Dannals RF et al. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in living brain. Science 1984; 226: 1393-1396.